Rapidly Growing Mycobacteria (RGM) And Pacemaker Infection
Rayane Nassar, MD and Maha Assi, MD, MPH

Introduction

- Infection rates of pacemakers and defibrillators range from 1% to 7%.
- RGM known as *M. fortuitum, M. abscessus, M.chelonae* are uncommon pathogens of pacemaker infection.

Case Presentation

- A 68-year-old male with dilated cardiomyopathy s/p defibrillator placement 3 years prior was admitted with a five-month history of fever, chills, and myalgias.
- Outside records:
  - Blood culture positive for *M. fortuitum*, 5 months prior
- On admission:
  - BP: 93/53 mmHg
  - No focal signs of infection of generator pocket
  - WBC: 4900 /µl
  - Hb: 10.1 g/dl
  - Platelets: 83000/µl
  - Blood culture grew *M. fortuitum*
- Device infection was suspected.
- Defibrillator was removed and a temporary pacemaker placed.
- Defibrillator leads grew *M. fortuitum*.
- Therapy started with amikacin 10mg/kg IV daily, cefoxitin 2 grams IV q 8 hours, and Levaquin 750 mg IV daily.
- Blood culture was negative after one week of therapy.

Discussion

- RGM are ubiquitous in the environment and have an indolent disease course.
- It shows clinical signs after trauma or surgery.
- Disseminated disease is seen in immuno-compromised patients.
- Review of the English literature revealed 5 cases of RGM pacemaker infection.
- Infections are mainly nosocomial (within 6 months), but delayed onset was also reported (>1 year).
- Suspect infection in patients with implanted cardiovascular devices even with absence of localized signs of infection on the generator site.
- Optimal treatment is removal of all device hardware, with empirical antibiotics until susceptibility results.
- RGM are in general susceptible to amikacin, fluoroquinolones, cefoxitin and linezolid
- The duration of therapy is 6 to 12 months.

Take Home Messages

- Suspect device infection in patients with positive blood culture for RGM even in the absence of pocket inflammation.
- Removal of hardware is crucial for curative therapy.
- Start empiric IV antibiotics until susceptibility testing is available.

References